Video: Latest Treatment for Hep C.

Salacyn Cream

Generic Name: salicylic acid
Dosage Form: cream

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

SALACYN™ 6% CREAM
SALACYN™ 6% LOTION

(6% Salicylic Acid)

Rx only

FOR DERMATOLOGICAL USE ONLY.
NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE.

Salacyn Cream Description

SALACYN™ 6% CREAM contains 6% Salicyclic Acid USP incorporated into a specially formulated oil and water emulsion vehicle consisting of Ammonium Lactate, Cetearyl Alcohol and PEG-3 Distearoylamidoethylmonium Methosulfate and Polysorbate 60, Cetearyl Alcohol, Cetyl Alcohol, Dimethicone 350, Disodium EDTA, Glycerin, Glyceryl Stearate SE, Methylparaben, Mineral Oil, PEG-100 Stearate, Phenoxyethanol, Propylparaben, Purified Water and Trolamine.

Slideshow: HealthQuiz: Basics About Stroke Signs and Symptoms

SALACYN™ 6% LOTION contains 6% w/w Salicylic Acid USP incorporated into a specially formulated oil and water emulsion vehicle consisting of of Ammonium Lactate, Cetearyl Alcohol and PEG-3 Distearoylamidoethylmonium Methosulfate and Polysorbate 60, Cetyl Alcohol, Dimethicone 350, Disodium EDTA, Glycerin, Glyceryl Stearate SE, Methylparben, Mineral Oil, PEG-100 Stearate, Propylparaben, Purified Water and Trolamine.

Salicylic Acid is the 2-hydroxy derivative of benzoic acid having the following structure:

Salacyn Cream - Clinical Pharmacology

Salicylic Acid has been shown to produce desquamation of the horny layer of the skin while not effecting qualitative or quantitative changes in the structure of the viable epidermis. The mechanism of action has been attributed to a dissolution of intercellular cement substance. In a study of the percutaneous absorption of salicylic acid in a 6% salicylic acid gel in four patients with extensive active psoriasis. Taylor and Halprin showed that the peak serum salicylate levels never exceeded 5 mg/100 ml even though more than 60% of the applied salicylic acid was absorbed. Systemic toxic reactions are usually associated with much higher serum levels (30 to 40 mg/100ml). Peak serum levels occurred within five hours of the topical application under occlusion. The sites were occluded for 10 hours over the entire body surface below the neck. Since salicylates are distributed in the extracellular space, patients with a contracted excellular space due to dehydration or diuretics have higher salicylate levels than those with a normal extracellular space. (SEE PRECAUTIONS).

The major metabolites identified in the urine after topical administration are salicyluric acid (52%), salicylate glucuronides (42%) and free salicylic acid (6%). The urinary metabolites after percutaneous absorption differ from those after oral salicylate administration; those derived from percutaneous absorption contain more salicylate glucuronides and less salicyluric and salicylic acid. Almost 95% of a single dose of salicylate is excreted within 24 hours of its entrance into the extracellular space.

Fifty to eighty percent of salicylate is protein bound to albumin. Salicylates compete with the binding of several drugs and can modify the action of these drugs; by similar competitive mechanisms other drugs can influence the serum levels of salicylate. (SEE PRECAUTIONS).

Indications and Usage for Salacyn Cream

FOR DERMATOLOGIC USE

SALACYN™ 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris and psoriasis (including body, scalp, palms and soles).

FOR PODIATRIC USE

SALACYN™ 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares.

Contraindications

SALACYN™ 6% should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients. SALACYN™ 6% should not be used in children under 2 years of age.

Warnings

Prolonged and repeated daily use over large areas, especially in children and those patients with significant renal or hepatic impariment could result in salicylism. Concomitant use of other drugs which may contribute to elevated serum salucylate levels should be avoided where the potential for toxicity is present. In children under 12 years of age and those patients with renal of hepatic impairment to the area to be treated should be limited and the patient monitored closely for signs of salicylate toxicity; nausea, vomiting, dizziness, loss of hearing, tinnitus, lethargy, hyperpnea, diarrhea, and psychic disturbances. In the event of salicylic acid toxicity, the use of SALACYN™ 6% should be discontinued. Fluids should be administered to promote urinary execration. Treatment with sodium bicarbonate (oral or intravenous) should be instituted as appropriate. Patients should be cautioned against the use of oral aspirin and other salicylate containing medications, such as sports injury creams, to avoid additional excessive exposure to salicylic acid. Where needed, aspirin should be replaced by an alternative non-steroidal anti-inflammatory agent that is not salicylate based. Patients should be advised not to apply occlusive dressings, clothing or other occlusive topical products such as petrolatum-based ointments to prevent excessive systemic exposure to salicylic acid. Excessive application of the product other than is needed to cover the affected area will not result in a more rapid therapeutic benefit.

Due to the potential risk of developing Reye's syndrome, salicylate products should not be used in children and teenagers with varicella or influenza, unless directed by a physician.

Precautions

For external use only. Avoid contact with eyes and other mucous membranes.

DRUG INTERACTIONS

The following interactions are from a published review and include reports concerning both oral and topical salicylate administration. The relationship of these interactions to the use of SALACYN™ 6% is not known.

  1. Due to the competition of salicylate with other drugs for binding to the serum albumin the following drug interactions may occur:
    DRUG DISCRIPTION OF INTERACTION
    Sulfonylureas Hypoglycemia potentiated
    Methotrexate Decreases tubular reabsorption; clinical toxicity from methotrexate can result.
    Oral Anticoagulants Increased bleeding
  2. Drugs changing salicylate levels by altering renal tubular reabsorption:
    DRUG DISCRIPTION OF INTERACTION
    Corticosteroids Decreases plasma salicylate level; tapering doses of steroids may promote salicylism.
    Acidifying agents Increases plasma salicylate levels.
    Alkcanizing agents Decreased plasma salicylate levels.
  3. Drugs with completed interactions with salicylates:
    DRUG DISCRIPTION OF INTERACTION
    Heparin Salicylate decreases platelet adhesiveness and inteferes with hemostasis in heparin treated patients.
    Pyrazinamide Inhibits pyrazinamide induced hyperuricemia.
    Uricosuric Agents Effect of probenemide, sulfinpyrazone and phenylbutazone inhibited.

The following alterations of laboratory tests have been reported during salicylate therapy:

LABORATORY TESTS EFFECT OF SALICYLATES
Thyroid Function Decreased PBI; increased T3 uptake.
Urinary Sugar False negative with glucose oxidase; false positive with Clinitest with high-dose salicylate therapy (2-5g q.d.).
5-Hydroxyindole acetic acid False negative with fluorometric test.
Acetone, ketone bodies False positive FeCl3 in Gerhardt reaction; red color persist with boiling.
17-OH corticosteroids False reduced values with >4.8g. q.d. salicylate.
Vanilmandelic acid False reduced values.
Uric acid May increase or decrease depending on dose.
Prothrombin Decreased levels; slightly increased prothrombin time.

PREGNANCY

(Category C)

Salicylic acid has been shown to be teratogenic in rats and monkeys. It is difficult to extrapolate from oral doses of acetylsalicylic acid used in these studies to topical administration as the oral does to monkeys may represent six times the maximal daily human does of salicylic acid when applied topically over a large body surface. There are no adequate and well-controlled studies in pregnant women. SALACYN™ 6% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

NURSING MOTHERS

Because of the potential for serious adverse reactions in nursing infants from the mother's use of SALACYN™ 6%, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. If used by nursing mothers, it should not be used on the chest area to avoid accidental contamination of the child.

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY

No data are available concerning potential carcinogenic or reproductive effects of SALACYN™ 6%. It has been shown to lack mutagenic potential in the Ames Salmonella test.

Adverse Reactions

Excessive erythema and scaling conceivably could result from the use on open skin lesions.

Overdosage

SEE WARNINGS.

Salacyn Cream Dosage and Administration

The preferable method of use is to apply SALACYN™ 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for at least five minutes prior to application. The medication is washed off in the morning and if excessive drying and/or irritation is observed, a bland cream or lotion may be applied. Once clearing is apparent, the occasional use of SALACYN™ 6% will usually maintain the remission. In those areas where occulsion is difficult or impossible, application may be made more frequently; hydration by wet packs or baths prior to application apparently enhances the effect. (SEE WARNINGS). Unless hands are being treated, hands should be rinsed thoroughly after application. Excessive repeated application of SALACYN™ 6% will not necessarily increase its therapeutic benefit, but could result in increased local intolerance and systemic adverse effects such as salicylism.

How is Salacyn Cream Supplied

SALACYN™ 6% CREAM is available in 400 gram bottles, NDC 58980-631-90.

SALACYN™ 6% LOTION is available in 14 fl oz (414ml) bottles, NDC 58980-630-14

Store at controlled room temperature 20° - 25°C (68° - 77°F). Do not freeze.

Distributed by
STRATUS
PHARMACEUTICALS INC

Manufactured by
Sonar Products Inc.
Carlstadt, NJ 07072
exclusively for
Stratus Pharmaceuticals Inc.
12379 Southwest 130th Street
Miami, Florida 33186-6208

Customer Service
Telephone: 1-800-442-7882
Fax: 305-254-6875

©2008 Stratus Pharmaceuticals Inc.
SA6-IN200812.

PRINCIPAL DISPLAY PANEL - 400 g Bottle Label

NDC 58980-631-90

Rx only

SALACYN
CREAM

(6% Salicylic Acid)

STRATUS
PHARMACEUTICALS INC

Net WT. 400 grams

PRINCIPAL DISPLAY PANEL - 414 mL Bottle Label

NDC 58980-630-14

Rx only

SALACYN
LOTION

(6% Salicylic Acid)

STRATUS
PHARMACEUTICALS INC

Net WT. 14.0 fl. oz. (414 mL)

SALACYN 
salicylic acid cream
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:58980-631
Route of Administration TOPICAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Salicylic Acid (Salicylic Acid) Salicylic Acid 24 g  in 400 g
Inactive Ingredients
Ingredient Name Strength
Ammonium Lactate  
Cetostearyl Alcohol  
Polysorbate 60  
Glycerin  
Cetyl Alcohol  
Mineral Oil  
Dimethicone 350  
Water  
Edetate Disodium  
Glyceryl Monostearate  
Methylparaben  
Polyoxyl 100 Stearate  
Phenoxyethanol  
Propylparaben  
Trolamine  
Product Characteristics
Color WHITE Score     
Shape Size
Flavor Imprint Code
Contains         
Packaging
# Item Code Package Description
1 NDC:58980-631-90 400 g in 1 BOTTLE, PLASTIC
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
UNAPPROVED DRUG OTHER 03/23/2009
SALACYN 
salicylic acid lotion
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:58980-630
Route of Administration TOPICAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Salicylic Acid (Salicylic Acid) Salicylic Acid 24.84 mg  in 414 mL
Inactive Ingredients
Ingredient Name Strength
Ammonium Lactate  
Cetostearyl Alcohol  
Polysorbate 60  
Glycerin  
Cetyl Alcohol  
Mineral Oil  
Dimethicone 350  
Water  
Edetate Disodium  
Glyceryl Monostearate  
Methylparaben  
Polyoxyl 100 Stearate  
Propylparaben  
Trolamine  
Product Characteristics
Color WHITE Score     
Shape Size
Flavor Imprint Code
Contains         
Packaging
# Item Code Package Description
1 NDC:58980-630-14 414 mL in 1 BOTTLE, PLASTIC
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
UNAPPROVED DRUG OTHER 03/23/2009
Labeler - Stratus Pharamceuticals, Inc (789001641)
Registrant - Sonar Products, Inc (104283945)
Establishment
Name Address ID/FEI Operations
Sonar Products, Inc 104283945 MANUFACTURE
Revised: 11/2010
 
Stratus Pharamceuticals, Inc
Hide
(web5)